1. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. (March 2022) Authors: Marron, Thomas U; Fiel, Maria Isabel; Hamon, Pauline; Fiaschi, Nathalie; Kim, Edward; Ward, Stephen C; Zhao, Zhen; Kim, Joel; Kennedy, Paul; Gunasekaran, Ganesh; Tabrizian, Parissa; Doroshow, Deborah; Legg, Meredith; Hammad, Ashley; Magen, Assaf; Kamphorst, Alice O; Shareef, Muhammed; Gupta, Nami... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 3(2022) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗